Navigation Links
Abbott to Acquire Nutrition Businesses, Expanding Presence in India
Date:7/28/2009

ABBOTT PARK, Ill., July 28 /PRNewswire-FirstCall/ -- Abbott announced today a definitive agreement to acquire the nutrition businesses of Wockhardt Limited, Carol Info Services Limited, and certain Wockhardt subsidiaries and group companies for consideration totaling approximately US$130 million in cash.

Wockhardt, based in Mumbai, India, has a significant presence in India's pediatric and adult nutrition segments with infant formulas, weaning foods and adult protein supplements. These products hold the number two position in India's pediatric nutrition category with Farex(R), Dexolac(R) and Nusobee(R) infant formulas and Farex(R) weaning cereal. The adult protein supplement, Protinex(R), is the segment leader. These transactions also include nutrition manufacturing facilities located in Lalru and Jagraon, India.

"This acquisition is an excellent strategic fit for Abbott to accelerate growth of its nutrition business in India, where the nutritional market is expected to experience strong growth in the coming years," said Holger Liepmann, executive vice president, Global Nutrition, Abbott. "Combining these trusted nutrition products, local manufacturing capability and commercial infrastructure with Abbott's existing pediatric and adult nutrition offerings positions Abbott very well to serve Indian consumers."

Abbott's international nutrition business is an important growth driver for the company and has had particularly strong growth in China, Southeast Asia and Latin America in recent years.

The acquisition includes approximately 600 employees in total. Abbott has approximately 1,500 employees in India across all of its businesses and has been operating in India since 1910. Abbott offers Isomil(R), PediaSure(R), Ensure(R) and Glucerna(R) in India and plans to introduce additional products from its broad-based nutritional portfolio to Indian consumers in the coming years.

Financial Terms

Under terms of the agreement, Abbott will acquire the nutrition businesses of Wockhardt Limited, Carol Info Services Limited, and certain Wockhardt subsidiaries and group companies for consideration totaling approximately US$130 million in cash. There will be no impact to Abbott's previously issued earnings-per-share guidance for the full-year 2009.

These transactions are subject to customary closing conditions and various approvals. Abbott expects the transactions to close in the second half of 2009. The transactions are not being conducted by Abbott's publicly traded subsidiary, Abbott India, Ltd.

About Abbott

Abbott is a global, broad-based health care company devoted to the discovery, development, manufacture and marketing of pharmaceuticals and medical products, including nutritionals, devices and diagnostics. The company employs more than 72,000 people and markets its products in more than 130 countries.

Abbott's news releases and other information are available on the company's Web site at www.abbott.com.

Abbott Forward Looking Statement

Some statements in this news release may be forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. Abbott cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those indicated in the forward-looking statements. Economic, competitive, governmental, technological and other factors that may affect Abbott's operations are discussed in Item 1A, "Risk Factors," to our Annual Report on Securities and Exchange Commission Form 10-K for the year ended Dec. 31, 2008, and are incorporated by reference. Abbott undertakes no obligation to release publicly any revisions to forward-looking statements as a result of subsequent events or developments.


'/>"/>
SOURCE Abbott
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Abbott and Medtronic Reach Agreement on Global Patent Disputes
2. NeoGenomics Enters into Strategic Supply Agreement with Abbott for Development of a Melanoma Cancer Test
3. Abbott Introduces Molecular Diagnostic System Intended for Broad Identification of Infectious Agents
4. Abbott Launches New Instrument to Complete Family of ARCHITECT Immunochemistry Analyzers
5. Abbott Reports Strong Second Quarter Results; Confirms Double-Digit Earnings Growth Outlook for 2009
6. Abbott and Oasmia Pharmaceutical Announce Exclusive Distribution Agreement for Paccal(R) Vet, a New Chemotherapeutic Agent for Dogs
7. Abbott Hosts Conference Call for Second-Quarter Earnings
8. Abbott Receives CE Mark for Companys Next-Generation XIENCE PRIME(TM) Drug Eluting Stent, Advancing Leadership Position
9. Schmidt & Clark, LLP: FDA Reports Show Abbott Labs Subsidiary Failed to Disclose Parasite Eye Infections Tied to Contact Lens Solution
10. Abbott Initiates Trial of Next-Generation XIENCE PRIME(TM) Drug Eluting Stent, Building Upon Superior Outcomes from SPIRIT Family of Trials
11. Abbott Declares 342nd Consecutive Quarterly Dividend
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/22/2017)... , ... February 22, 2017 , ... ... issues related to spine practices, is featuring Michigan neurosurgeon Jay Jagannathan, M.D., as ... one of a small number of neurosurgeons in Michigan performing minimally invasive back ...
(Date:2/22/2017)... ... February 22, 2017 , ... Michael J. Hennessy ... platform connecting healthcare technology professionals and other key stakeholders with an array of ... starting on March 1, announced Michael J. Hennessy, Jr., president of MJH Associates. ...
(Date:2/22/2017)... ... 22, 2017 , ... Super-Sod will attend the Athens Home Show with a ... A shift from Super-Sod’s simple Athens Home Show booth of 2016, this year’s exhibit ... plant manager Chris Roquemore constructed furniture from recycled pallet wood at the Super-Sod farm ...
(Date:2/22/2017)... ... 2017 , ... FPS is a nonprofit mental health agency ... 1977, our organization was at the forefront in working with veterans with PTSD-related ... evident and served as the catalyst for the establishing the agency. , Run ...
(Date:2/22/2017)... ... February 22, 2017 , ... ... Safety, patient advocates stress that the patient context (age, illness and life choices) ... reasons to mitigate their occurrence. In addition, all too often, studies ...
Breaking Medicine News(10 mins):
(Date:2/22/2017)... ENGLEWOOD, Colo. , Feb. 22, 2017  Aytu ... on global commercialization of novel products in the field ... sales team to up to 42 account managers from ... footprint. The sales force expansion is ... both prescriptions and revenues, an indication of increasing acceptance ...
(Date:2/22/2017)... According to a new market research report "Process Analytical Technology ... (Analyzers, Probes & Sensors), End - User (Pharmaceutical Manufacturers, CRO & CMO) ... poised to reach USD 3.30 Billion by 2021 from USD 1.77 Billion ... Continue Reading ... ...
(Date:2/22/2017)... WOONSOCKET, R.I. , Feb. 22, 2017  CVS ... announce the removal of partially hydrogenated oils (PHO), the ... from all its exclusive store brands food products. The ... options which are free from artificial trans fats. This comes ... and Drug Administration,s deadline of June 2018 for processed ...
Breaking Medicine Technology: